United States: Clarion Call For Diagnostics

As the world continues to become more interconnected, the ability of health organizations to deal with world health threats is growing ever more complicated. Existing and emerging pathogens, which do not respect national borders, will rapidly create epidemics, and the world health community will continue to be insufficiently prepared to deal with them effectively.

It is obvious that the most effective way to deal with the threat from the spread of infectious diseases is at their source. Accordingly, diagnostics should be at the first line of defense. Diagnostics play a crucial role in case management, disease control and surveillance, and the absence of effective diagnostics inhibits populations from receiving effective treatment. When there are no effective vaccines or therapeutics, the only measure available to stop the spread of infections is the rapid identification of infected patients.

The Ebola epidemic, spread through physical contact and claiming over 10,000 lives, is just one of several flare-ups this century. Many of the lives lost could have been saved had an effective rapid diagnostic test been available to confirm suspected infection, isolate infected individuals for treatment and prevent them from continuing to infect others.

Imagine what the death toll would have been if Ebola were spread through the air, like Middle East respiratory syndrome coronavirus (MERS-CoV), with a single infected individual in a public place capable of infecting an untold number of persons. The MERS-CoV outbreak in South Korea quickly claimed 24 lives and required quarantining of villages and the closure of thousands of schools.

Emerging diagnostics also have the potential to be at the forefront of battling antimicrobial resistance by providing rapid and precise diagnosis, enabling early refinement of the antibiotic therapy. It is estimated that more than 500,000 deaths from resistant infections occur in the world annually. This is caused to a large extent by a failure to accurately diagnose the infections, resulting in the overuse of the already dwindling arsenal of effective antibiotics and the further spread of resistance.

In addition, experience has shown that disease threats can impose a devastating impact on health systems in low- and middle-income countries, as well as enormous economic impact on the global economy. The economic impact from Ebola on West Africa has yet to play out, but a report from the United Nations estimated that it will cost up to $15 billion over the next three years from the loss of trade, investment and tourism.

On a global scale, the SARS breakout is estimated to have cost the world's economy $40 billion in a mere four months. And a worldwide flu epidemic, according to the World Bank, would reduce global wealth by as much as $3 trillion.

The world health community has acknowledged that effective diagnostics are needed to address the diseases afflicting low- and middle-income countries. However, meaningful efforts to provide resources for their development are lacking.

Take for example the Global Health Security Agenda, organized in 2014 by the Centers for Disease Control and Prevention to track the spread of infections and enable the deployment of effective countermeasures. While diagnostics were recognized as an important ingredient to success, the initiative is pitifully underfunded in general and is thus hampered from providing meaningful funds for diagnostic development.

Other strategies need to be pursued to bring additional resources to bear on the problem.


While the time, expense and development complexity for a diagnostic is significantly less than the cost of developing a vaccine or therapeutic, it can run into the tens of millions of dollars and is a significant barrier for diagnostic manufacturers, many of which are small companies with novel technology but only limited capital.

The Ebola crisis, perhaps because of the fear it engendered around the world, has been a catalyst for over 70 companies to include Ebola diagnostics in their R&D portfolios, despite the dearth of external funding to defray investment costs.

However, other infections that take an even greater toll on world health do not garner sufficient funding for diagnostics, such as those targeted by the London Declaration on Neglected Tropical Diseases: HCV, tuberculosis, malaria and HIV.

Take for example HCV. There are an estimated 130-150 million infected individuals worldwide and 350,000-500,000 deaths annually, mostly in low- or middle-income countries. There is a need to rapidly identify patients who are eligible for treatment; however, HCV is severely underdiagnosed because the existing tests are complex, expensive and can be performed only at centralized laboratories, which are lacking in many of these countries.

Historically the public sector and the Bill & Melinda Gates Foundation have been the principal funders of diagnostics for the developing world; however, there is no reason why industries with a high burden of incidence of these communicable diseases among employees cannot be tapped to provide funding. For example, the mining industry in South Africa and other endemic countries should have an economic and humanitarian interest in safeguarding the health of employees.

Also, while many governments in countries where certain diseases are endemic may not be able to provide funding for diagnostics, they may have the ability to contribute clinical trial support in their own facilities, thereby defraying a good part of the cost of diagnostic development. Even if economic programs can be devised to induce manufacturers to undertake development of diagnostics, the challenge of successful development and introduction should not be underestimated. For a diagnostic to be effective in low- and middle-income countries, it needs to meet the World Health Organization's ASSURED criteria: affordable, sensitive, specific, user-friendly, robust and rapid, equipment-free and deliverable.

In addition, these diagnostics need to perform under difficult conditions such as villages across Africa and other parts of the world where there may be a dearth of health facilities with access to reliable power sources.

Meeting a target product profile for these settings is a major challenge for developers. Thus providing manufacturers with scientific and regulatory expertise through not-for-profit organizations, such as FIND (the Foundation for Innovative New Diagnostics), can reduce costs and development time.

Organizations such as FIND can catalyze development by identifying needed diagnostic solutions; and provide technical, disease and market and regulatory expertise; and remove barriers to development. They also can guide policy on use and market entry, support uptake and appropriate use, and help improve understanding of the value of diagnostics and strengthen commitment to their funding and use.

An example of the success of this type of support from FIND is the Xpert MTB/RIF tuberculosis assay from Cepheid Inc. It transformed drug susceptibility tests to enable detection of TB and resistance to rifampicin, the key component in the established first-line treatment regimen. Xpert replaced a test that used to take 120 days at a reference-level laboratory; now test results are available in 90 minutes and can be done at local laboratories. The test was rolled out to over 120 countries in less than two years. Other examples of diagnostics that were developed by FIND for low- and middle-income countries were in malaria and sleeping sickness.

A broad coalition of stakeholders, including diagnostic-focused product development partnerships, the WHO, governments, ministries of health and public and private donors — if collaborating regularly — can leverage their respective resources and expertise to enhance the development, introduction and rapid uptake of a new diagnostic.

Originally published in BioCentury on July 27

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions